Single-Cell Transcriptomic Identification of Mast Cell Tryptase (TPSAB1) as a Therapeutic Target in Human Nasal Polyps for Allergic Rhinitis and Eosinophilic Chronic Rhinosinusitis

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Allergic rhinitis and eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP) represent a spectrum of type 2 upper airway inflammatory disease affecting hundreds of millions of patients worldwide. Mast cells are key effectors of nasal type 2 inflammation, yet cell-type-specific druggable targets in human nasal polyp mast cells have not been systematically identified at single-cell resolution. Here we apply a computational drug screening pipeline to the human nasal polyp scRNA-seq dataset GSE156285 to identify mast cell tryptase (TPSAB1) as the top druggable target in mast cell-enriched clusters. ScVI dimensionality reduction and Leiden clustering of 1,635 high-quality cells identified 12 populations; a mast cell / type 2 inflammation signature identified clusters 5, 3, and 7 as mast cell-enriched populations co-expressing TPSAB1, TPSB2, CPA3, MS4A2, HDC, HPGDS, and IL1RL1. Wilcoxon differential expression yielded 245 upregulated genes. ChEMBL drug screening identified 674 NOVEL_ALL TPSAB1 inhibitor candidates, all patent-clear for the nasal / allergic rhinitis / eCRSwNP indication. Lead compounds: CHEMBL46809 (pChEMBL 10.15), CHEMBL297220 (pChEMBL 9.40), CHEMBL310290 (pChEMBL 9.22), CHEMBL4460840 (CPA3, pChEMBL 9.41). TPSAB1 inhibition targets PAR-2-mediated neurogenic inflammation and epithelial remodeling — mechanisms unaddressed by any approved nasal therapy. Patent pending: USPTO App. No. 64/013,288. Provisional spec: https://doi.org/10.5281/zenodo.19169012. Pipeline: github.com/glenritschel/crswn-scrna.

Fields of Study & Subjects

Sinusitis and nasal conditions Mast cells and histamine Asthma and respiratory diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN
Document type
Preprint